

## Can We Do Better in IgAN?

### **Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial**

Heerspink HJL, Radhakrishnan J, Alpers CE, et al; PROTECT Investigators. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. *Lancet*. 2023;401(10388):1584-1594. doi:10.1016/S0140-6736(23)00569-X

Link: <https://pubmed.ncbi.nlm.nih.gov/37015244/>

### **Long-term outcomes in IgA nephropathy**

Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in IgA nephropathy. *Clin J Am Soc Nephrol*. 2023;18(6):727-738. doi:10.2215/CJN.000000000000135

Link: <https://pubmed.ncbi.nlm.nih.gov/37055195/>

### **Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases**

Rovin BH, Adler SG, Barratt J, et al. Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. *Kidney Int*. 2021;100(4):753-779. doi:10.1016/j.kint.2021.05.015

Link: <https://pubmed.ncbi.nlm.nih.gov/34556300/>

### **Evaluating a new international risk-prediction tool in IgA nephropathy**

Barbour SJ, Coppo R, Zhang H, et al; International IgA Nephropathy Network. Evaluating a new international risk-prediction tool in IgA nephropathy. *JAMA Intern Med*. 2019;179(7):942-952. doi:10.1001/jamainternmed.2019.0600

Link: <https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2730331>

### **Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores)**

Schimpf JI, Klein T, Fitzner C, et al. Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores). *BMC Nephrol*. 2018;19(1):328. doi:10.1186/s12882-018-1128-6

Link: <https://bmcnephrol.biomedcentral.com/articles/10.1186/s12882-018-1128-6>

### **Risk factors for progression of chronic kidney disease**

Staples A, Wong C. Risk factors for progression of chronic kidney disease. *Curr Opin Pediatr.* 2010;22(2):161-169. doi:10.1097/MOP.0b013e328336ebb0

Link: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948868/>